KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $30.60 Consensus Target Price from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been assigned a consensus rating of “Hold” from the nine brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $30.60.

A number of equities analysts recently commented on the stock. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Finally, HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $37.00 to $27.00 in a research note on Friday, May 1st.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Nicole Sweeny sold 1,862 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the transaction, the insider owned 51,391 shares of the company’s stock, valued at approximately $1,039,126.02. This trade represents a 3.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,686 shares of the stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $54,310.92. Following the completion of the sale, the insider owned 142,547 shares of the company’s stock, valued at approximately $2,882,300.34. The trade was a 1.85% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 240,606 shares of company stock worth $4,210,242. 4.30% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors have recently made changes to their positions in KALV. Parallel Advisors LLC boosted its position in shares of KalVista Pharmaceuticals by 45.8% during the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 589 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $55,000. Royal Bank of Canada boosted its position in shares of KalVista Pharmaceuticals by 137.0% during the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after acquiring an additional 1,686 shares in the last quarter. Finally, Truvestments Capital LLC boosted its position in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $26.79 on Thursday. The company has a 50 day moving average price of $21.54 and a 200 day moving average price of $17.43. KalVista Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $26.85. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $39.17 million for the quarter, compared to analysts’ expectations of $39.03 million. Research analysts forecast that KalVista Pharmaceuticals will post -0.96 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.